{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:14:51Z","timestamp":1789226091928,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ijantimicag.2024.107294","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T02:19:09Z","timestamp":1722997149000},"page":"107294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations"],"prefix":"10.1016","volume":"64","author":[{"given":"Shanshan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-0933","authenticated-orcid":false,"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-7773","authenticated-orcid":false,"given":"Haiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107294_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.addr.2016.04.027","article-title":"Stem cell-based therapies for HIV\/AIDS","volume":"103","author":"Pernet","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0002","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of virologic failure and HIV drug resistance","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0003","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV drug resistance\u2014an emerging threat to epidemic control","volume":"377","author":"Beyrer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0004","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1074\/jbc.REV119.006901","article-title":"Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition","volume":"294","author":"Engelman","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0005","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0006","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/AAC.00611-20","article-title":"HIV-1 integrase inhibitors that are active against drug-resistant integrase mutants","volume":"64","author":"Smith","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0007","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0008","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society\u2014USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0011","doi-asserted-by":"crossref","first-page":"ofz060","DOI":"10.1093\/ofid\/ofz060","article-title":"Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis","volume":"6","author":"Kamelian","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drup.2010.05.001","article-title":"Resistance to HIV-1 integrase inhibitors: a structural perspective","volume":"13","author":"Mouscadet","year":"2010","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2047-783X-14-S3-30","article-title":"The use of integrase inhibitors in treatment-experienced patients","volume":"14","author":"Gatell","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014-2018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0016","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4102\/sajhivmed.v23i1.1398","article-title":"Low-level viraemia despite emergence of dolutegravir-resistant variants","volume":"23","author":"Botha","year":"2022","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0017","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jmv.25661","article-title":"Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa","volume":"92","author":"Onoriode Digban","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0018","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0019","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0b013e3181c42ea4","article-title":"Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy","volume":"54","author":"Hatano","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0022","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dkq350","article-title":"Integrase inhibitors in the treatment of HIV-1 infection","volume":"65","author":"Powderly","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0023","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0024","series-title":"HIV drug resistance: brief report 2024","year":"2024"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0026","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001-2017)","volume":"18","author":"Zuo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0028","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12981-016-0115-x","article-title":"Dolutegravir (DTG, S\/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Jiang","year":"2016","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160087","article-title":"Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: a subgroup meta-analysis of clinical trials","volume":"11","author":"You","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000001781","article-title":"Adverse drug reactions to integrase strand transfer inhibitors","volume":"32","author":"Lepik","year":"2018","journal-title":"Aids"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0031","unstructured":"U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. (2021). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. [accessed December 8, 2023]; Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines."},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0033","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/QAD.0000000000003866","article-title":"HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde","volume":"38","author":"Gon\u00e7alves","year":"2024","journal-title":"Aids"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0034","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1097\/QAD.0000000000000494","article-title":"Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis","volume":"28","author":"Pham","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates","volume":"23","author":"Rhee","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0036","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/ijms14035013","article-title":"Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in Northeastern South Africa","volume":"14","author":"Bessong","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0037","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"Smith","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0038","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/infdis\/jiac415","article-title":"HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention","volume":"226","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00053-23","article-title":"Extended analysis of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"67","author":"Marzinke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0041","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0042","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0043","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s15010-016-0936-5","article-title":"Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013","volume":"45","author":"Zoufaly","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0044","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/COH.0b013e328331d4b1","article-title":"Resistance to novel drug classes","volume":"4","author":"Marcelin","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e3181e9a87a","article-title":"Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness","volume":"55","author":"Hu","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0046","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/JVI.06618-11","article-title":"Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo","volume":"86","author":"Fransen","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0047","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0048","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review","volume":"16","author":"Chu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0049","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2024.107294_bib0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","article-title":"Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants","volume":"15","author":"Smith","year":"2018","journal-title":"Retrovirology"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T06:16:52Z","timestamp":1736576212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0924857924002103"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107294","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107294"}}